NASDAQ · SNSE
Sensei Biotherapeutics, Inc.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
Loading market information…
NASDAQ · TRIB · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Trinity Biotech plc’s forward annual dividend is $33.00 per share, paid annual. The forward yield is 497.74% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Trinity Biotech plc’s next earnings report is currently expected on Dec 10, 2026, with estimated earnings per share of -$8.40. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Trinity Biotech plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q3 2024 | Nov 15, 2024 | -$13.74+15.15% vs estimate | $15.15M-8.17% vs estimate |
|---|
| Q2 2024 | Aug 14, 2024 | -$21.30-9.12% vs estimate | $15.84M-3.98% vs estimate |
|---|
| Q1 2024 | May 23, 2024 | -$11.22+37.67% vs estimate | $14.70M-8.1% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$1.01+$0.01 (+1.0%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.94% below the high.
$1.72-$0.02 (-1.15%)
Sintx Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.43% below the high.
$1.86+$0.03 (+1.64%)
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
$2.64-$0.34 (-11.41%)
Advanced Biomed Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 89.1% below the high.
$0.38+$0.01 (+1.6%)
Evogene Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.74% below the high.
$0.98-$0.08 (-7.79%)
BioNexus Gene Lab Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.72% below the high.
$2.31-$0.05 (-2.12%)
Beyond Air, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.66% below the high.
